The only currently available drug that effectively removes malaria hypnozoites from the
human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side …

Background The radical cure of Plasmodium vivax and P. ovale requires treatment with
primaquine or tafenoquine to clear dormant liver stages. Either drug can induce haemolysis …

Throughout many developing and tropical countries around the world, malaria remains a
significant threat to human health. One barrier to malaria elimination is the ability to safely …

Background Primaquine is an 8-aminoquinoline antimalarial. It is the only widely available
treatment to prevent relapses of Plasmodium vivax malaria. The 8-aminoquinolines cause …

Background Glucose-6-phosphate dehydrogenase deficiency (G6PD), an x-linked inherited
enzymopathy, is a barrier to malaria control because primaquine cannot be readily applied …

Primaquine and tafenoquine are the only licensed drugs with activity against Plasmodium
vivax hypnozoites but cause haemolysis in patients with glucose–6–phosphate …

Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most
widespread enzyme defect that can result in red cell breakdown under oxidative stress when …

Background To reduce the risk of drug-induced haemolysis, all patients should be tested for
glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing …

Primaquine is the only available antimalarial drug that kills dormant liver stages of
Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse …

Malaria remains a significant public health issue in Haiti, with chloroquine (CQ) used almost
exclusively for the treatment of uncomplicated infections. Recently, single dose primaquine …